Analysis of RPL37A, MTSS1, and HTRA1 expression as potential markers for pathologic complete response and survival

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

Medicine, Oncology, Cancer Pharmacology +12

Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study

Lisa A. Carey, Charles M. Perou, Chad Livasy et al. · JAMA · 2006 · 3.8K citations

Medicine, Biostatistics, Oncology +14

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im et al. · The Lancet Oncology · 2011 · 2.4K citations

Medicine, Oncology, Pharmacology +16

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

Maggie C.U. Cheang, Stephen Chia, David Voduc et al. · JNCI Journal of the National Cancer Institute · 2009 · 2.2K citations · Full text

Medicine, Cancer Biology, Oncology +17

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

Jenny C. Chang, Eric C. Wooten, Anna Tsimelzon et al. · The Lancet · 2003 · 885 citations

Life Sciences, Oncology, Pharmacology +16